Skip to Main Content

Giving the immunotherapy Opdivo, made by Bristol Myers Squibb, to lung cancer patients before surgery can help prevent the disease from coming back, a new study says.

It’s a step toward what doctors have hoped cancer therapies that harness the immune system could ultimately do. It’s  the same hope they have with every new drug, really: that they could be used in patients who were diagnosed early, perhaps curing a greater number.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment